The startup develops a cartilage-on-a-chip technology that utilizes scalable organ-on-a-chip models to replace traditional animal testing in arthritis research. This approach enables healthcare providers to evaluate personalized treatment responses more efficiently and cost-effectively.
Funding
$900K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional animal testing methods used in arthritis research are expensive, inefficient, and may not accurately reflect human responses to treatment. This can lead to increased costs and lower success rates in pharmaceutical drug development for arthritis treatments. Furthermore, current methods do not allow for personalized treatment strategies based on individual patient needs.
Solution
Pregenerate provides an organ-on-a-chip platform, Optimate OA™, that utilizes scalable models to simulate how cartilage cells respond to inflammation and various treatments in a life-like manner. This technology enables the stratification of patients into targeted treatment subgroups, facilitating personalized medicine approaches for arthritis. The platform replaces animal testing with human cells, reducing costs and improving the success rates of pharmaceutical research for arthritis treatments. By analyzing patient samples in a way that mimics the complexities of the human body, Pregenerate offers insights tailored to individual patients, allowing healthcare providers to evaluate personalized treatment responses more efficiently.
Target Audience
The primary target audience includes pharmaceutical companies conducting research and development for arthritis treatments, as well as healthcare providers seeking personalized medicine solutions for their patients.
Features
- Scalable organ-on-a-chip models that mimic the response of cartilage cells to inflammation and treatments.
- Optimate OA™ platform for analyzing individual patient responses to treatments.
- Laboratory Developed Test (LDT) dedicated to osteoarthritis patients' samples.
- Ability to stratify patients into targeted treatment subgroups for personalized medicine.
- Replacement of animal testing with human cells in pharmaceutical research.
- Mobile app for patients to monitor their disease, medication, and condition.